Over the last 30 years, concomitant with successful transnational disease control programs
across Latin America, Chagas disease has expanded from a neglected, endemic parasitic …

Chagas disease, caused by the protozoan Trypanosoma cruzi, is a lifelong and debilitating
illness of major significance throughout Latin America and an emergent threat to global …

Although the genome of Trypanosoma cruzi, the causative agent of Chagas disease, was
first made available in 2005, with additional strains reported later, the intrinsic genome …

The protozoan Trypanosoma cruzi almost invariably establishes life-long infections in
humans and other mammals, despite the development of potent host immune responses …

Chagas disease caused by the parasite Trypanosoma cruzi affects millions of people.
Although its first genome dates from 2005, its complexity hindered a complete assembly and …

Benznidazole is the main drug used to treat Trypanosoma cruzi infections. However,
frequent instances of treatment failure have been reported. To better understand potential …

During an infection the immune system produces pathogen-specific antibodies. These
antibody repertoires become specific to the history of infections and represent a rich source …

Chagas disease is a complex illness caused by the protozoan Trypanosoma cruzi
displaying highly diverse clinical outcomes. In this sense, the genome sequence elucidation …

There is no consensus on the diagnostic algorithms for many scenarios of Trypanosoma
cruzi infection, which hinders the establishment of governmental guidelines in endemic and …

Trypanosoma cruzi, the protozoan causative of Chagas disease (ChD), exhibits striking
genetic and phenotypic intraspecific diversity, along with ecoepidemiological complexity …